{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-22-000444","form_type":"8-K","ticker":"GMED","cik":"0001237831","company_name":"GLOBUS MEDICAL INC","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.895859+00:00","generated_at":"2026-06-22T02:58:38.073725+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Globus Medical Q3 net sales $254.1M (+10.6% YoY); lowers FY22 non-GAAP EPS guidance to $2.03","bullets":["Q3 net sales $254.1M, up 10.6% as-reported and 12.6% constant currency; GAAP net income $47.4M, +0.5% YoY.","GAAP diluted EPS $0.47, non-GAAP diluted EPS $0.50; non-GAAP adjusted EBITDA $82.8M (32.6% of sales).","U.S. Spine sales +9.0%, International Spine +11.1% as-reported (+24.8% constant currency); Enabling Technologies +19.0% to $24.1M.","FY 2022 net sales reaffirmed at $1.025B; non-GAAP diluted EPS guidance lowered to $2.03 from $2.10 due to currency and tax.","Company remains debt-free; operating cash flow $32.9M and free cash flow $20.9M in Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-22-000444","json":"https://secwatch.observer/filing/0001562762-22-000444.json","markdown":"https://secwatch.observer/filing/0001562762-22-000444.md","text":"https://secwatch.observer/filing/0001562762-22-000444.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1237831/000156276222000444/0001562762-22-000444-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1237831/000156276222000444/gmed-20221108x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:58:38.073725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"24f577b94a7686637f4b4bf72fc8fa55dbd92dc8","claim":"GLOBUS MEDICAL INC reported quarter ended September 30, 2022 results: revenue $254.1 million, net income $47.4 million, EPS $0.47. Guidance reaffirmed.","evidence_excerpt":"Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2022 .  · Worldwide net sales were $254.1 million , an increase of 10.6% , or 12.6% on a constant currency basis · GAAP net income for the quarter was $47.4 million · GAAP d iluted earnings per share (“ EPS ”) was $0.47 and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1237831/000156276222000444/0001562762-22-000444-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2022"},{"label":"Revenue","value":"$254.1 million"},{"label":"Net income","value":"$47.4 million"},{"label":"EPS","value":"$0.47"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}